InnoCare Pharma received approval from China’s CDE to begin a Phase III trial of its BCL2 inhibitor, ICP-248 (Mesutoclax), combined with the BTK inhibitor orelabrutinib. This trial will evaluate the combination as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients in China. The company believes this fixed-duration combination therapy could offer a deeper remission and potentially a clinical cure for patients without drug-resistant mutations.
This trial approval is crucial due to the rising incidence of CLL/SLL in China and the potential for this combination therapy to address an unmet need. Orelabrutinib is already approved and reimbursed in China for other lymphoma types, suggesting a potential pathway for rapid market access if the Phase III trial is successful. A successful trial outcome could shift the treatment paradigm for CLL/SLL towards a potentially curative approach rather than managing the disease chronically.
ICP-248 works by selectively inhibiting BCL2, a protein that regulates apoptosis (programmed cell death), and restoring normal apoptosis in cancer cells. Previous Phase II trial data for the combination of ICP-248 and orelabrutinib demonstrated promising efficacy and a favorable safety profile in CLL/SLL patients. InnoCare is also developing ICP-248 for other blood cancers, indicating a broader strategic focus on hematological oncology.
A positive outcome from this Phase III trial could solidify InnoCare’s position in the Chinese oncology market and establish the ICP-248 and orelabrutinib combination as a leading treatment for CLL/SLL. Further, the success could pave the way for global development of this combination therapy, potentially impacting CLL/SLL treatment worldwide. This trial also validates InnoCare’s strategy of developing synergistic combinations within its oncology pipeline.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
